The Caveolin-1 Binding Domain of HIV-1 Glycoprotein gp41 Is an Efficient B Cell Epitope Vaccine Candidate against Virus Infection
Authors:
- Ara G. HovanessianAHAra G. Hovanessian
- Jean-Paul BriandJBJean-Paul Briand
- Elias A. SaidElias A. Said
- Josette SvabJSJosette Svab
- Stephane FerrisSFStephane Ferris
- Hayet DaliHDHayet Dali
- Sylviane MullerSMSylviane Muller
- Claude DesgrangesCDClaude Desgranges
- Bernard KrustBKBernard Krust
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individualsVaccine, 2003
- Lipid rafts and HIV-1: from viral entry to assembly of progeny virionsJournal of Clinical Virology, 2001
- N- and C-domains of HIV-1 gp41: mutation, structure and functionsImmunology Letters, 2001
- Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug targetProceedings of the National Academy of Sciences, 1998
- Establishment of a Functional Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcription Complex Involves the CytoskeletonJournal of Experimental Medicine, 1998
- HIV-1 subtypes in Santiago, ChileAIDS, 1998
- Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical TrialsThe Journal of Infectious Diseases, 1997
- Core Structure of gp41 from the HIV Envelope GlycoproteinCell, 1997
- Identification of Peptide and Protein Ligands for the Caveolin-scaffolding DomainJournal of Biological Chemistry, 1997
- Inhibition of HIV Infection by Pseudopeptides Blocking Viral Envelope Glycoprotein-Mediated Membrane Fusion and Cell DeathVirology, 1996